Sodium Polystyrene Sulfonate
drugOn this page
Also known as Amberlite forte ir 120Amberlite ir 120Amberlite ir-120Amberlite ir120 hAmberlite irp-69Amberlite irp-69mAmberlite irp69Ir 120KalexateKayexalateKionexPolistirex acidPolystyrene sulfonatePolystyrene sulfonic acidPolystyrene sulphonateResonium aSodium polistirexSodium polystyrene sulphonate
Summary
Sodium Polystyrene Sulfonate (CHEMBL1201484) is an approved small molecule (ATC V03AE01); indicated across 3 conditions including pseudohypoaldosteronism and hyperphosphatemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V03AE01
- Indications: 3 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201484 |
| Name | Sodium Polystyrene Sulfonate |
| Type | Small molecule |
| Max phase | 4 |
| ATC | V03AE01 |
Also known as: Amberlite forte ir 120, Amberlite ir 120, Amberlite ir-120, Amberlite ir120 h, Amberlite irp-69, Amberlite irp-69m, Amberlite irp69, Ir 120, Kalexate, Kayexalate, Kionex, Polistirex acid
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| pseudohypoaldosteronism | 2 | MONDO:0018638 | MONDO:0018638 |
| hyperphosphatemia | 1 | MONDO:0000328 | MONDO:0000328 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| Not specified | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01866709 | PHASE4 | TERMINATED | Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia |
| NCT02065076 | PHASE4 | COMPLETED | Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients |
| NCT00004328 | PHASE2 | COMPLETED | Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I |
| NCT04566653 | Not specified | COMPLETED | Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia |
| NCT06029179 | Not specified | COMPLETED | SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.